Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy
Daniel Gordin(Helsinki University Hospital), George L. King(Joslin Diabetes Center), Hillary A. Keenan(Joslin Diabetes Center), Ronald St-Louis(Joslin Diabetes Center), Hetal Shah(Joslin Diabetes Center), I‐Hsien Wu(Joslin Diabetes Center), Yutong Dong(Joslin Diabetes Center), Monika A. Niewczas(Joslin Diabetes Center), Aimo Kannt(Goethe University Frankfurt), Takanori Shinjo(Kyushu Dental University), Peter S. Amenta(Tulane Medical Center), Megan J. Brissett(Joslin Diabetes Center), David Pober(Joslin Diabetes Center), Thorsten Sadowski(Sanofi (Germany)), Vanessa Bahnam(Joslin Diabetes Center), Jonathan M. Dreyfuss(Joslin Diabetes Center), Hui Pan(Université Paris Cité), Weier Qi(Joslin Diabetes Center), Kyoungmin Park(Joslin Diabetes Center), Samantha M. Paniagua(Joslin Diabetes Center), Liane J. Tinsley(Joslin Diabetes Center)
Cited by 88
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Retinopathy in Diabetes
|Diabetes Care|2004|1.1k